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Abstract
Rationale—Although airway inflammation begins early in life in children with chronic
respiratory diseases, current methods to assess this inflammation are invasive and entail significant
risk. Measurement of exhaled breath condensate (EBC) purines and other biomarkers offer a less
invasive method to assess airway inflammation; however, the feasibility and utility of EBC
biomarkers in young children has not been established.
Methods—EBC was collected from children <3 years old with cystic fibrosis or other lung
diseases during clinically indicated infant pulmonary function tests (iPFTs). EBC concentrations
of the purine biomarkers adenosine, adenosine monophosphate (AMP) and the dilution marker
urea were measured using mass spectrometry.
Results—EBC was successfully collected (average volume 330±170 μl) from preschool children
(age 2.3 ± 0.8 years) in 15 of 17 iPFTs. No significant changes in oxygen saturation (96.9±1.6
start, 96.8±1.7 end, p=0.389) or respiratory rate (35.2±7.5 start, 34.6±7.9 end, p=0.443) were
observed during collection. Adenosine and AMP were successfully measured in 13/15 samples (8
CF). EBC AMP to adenosine ratio (AMP/Ado) negatively correlated with forced expiratory
volume at 0.5 seconds (FEV0.5, r=−0.71, p<0.01) and positively with the ratio of residual volume
to total lung capacity (RV/TLC, r=0.66, p=0.015). These correlations remained statistically
significant in the subset with CF.
Conclusions—EBC can be safely collected and analyzed in preschool children using
commercially available equipment. The EBC AMP/Ado ratio correlates with measures of infant
lung function and may be a less invasive means of monitoring airway inflammation in this
population.
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Introduction
Cystic fibrosis (CF) lung disease begins in infancy and is characterized by persistent airway
inflammation even in the absence of respiratory symptoms1-4. Readily measured biomarkers
of inflammation are needed to monitor disease progression in this vulnerable population;
however assessing airway biomarkers in this population is challenging. The gold standard
has classically been collecting bronchoalveolar lavage fluid, but this methodology is too
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invasive for routine use5,6 . Most preschool children also cannot expectorate sputum even
after induction with hypertonic saline7.
Exhaled breath condensate (EBC) is a simple, non-invasive means of monitoring airway
disease pathology in older children and adults. Our previous studies13, 14 have demonstrated
that mass spectrometry can be utilized to perform quantitative analyses of multiple EBC
biomarkers such as the adenyl purines, adenosine and adenosine monophosphate (AMP)
with simultaneous measurement of the dilution marker urea. Adenyl purines are released
onto the airway surfaces by airway epithelial and inflammatory cells where they act as
signaling molecules to regulate host defenses. Multiple studies suggest that airway purines
correlate with neutrophilic airway inflammation and EBC purines are elevated in subjects
with airways disease such as CF15, asthma28 and chronic obstructive pulmonary disease 22.
While the potential value of EBC biomarkers has been demonstrated in older children and
adults, there are few established methods for EBC biomarker evaluation in infants and
preschoolers largely because of the challenges in obtaining adequate samples from this
uncooperative cohort. Furthermore, many previously described methods for EBC collection
in this age group rely on novel devices developed at the institution conducting the study,
limiting the ability to generalize methods 8-11. In addition, the small volumes of EBC
recovered coupled with the low concentrations of biomarkers make detection challenging5.
In this study we developed a method for measuring biomarkers in EBC collected from
young children undergoing clinically indicated infant pulmonary function testing (iPFTs)
using a commercially available collection device (RTube, Respiratory Research, Inc.,
Charlottesville, VA). We focused on purines based on our past success evaluating EBC
purines as biomarkers of respiratory disease 13, 22, using mass spectrometry to assess the
EBC concentrations of the purines adenosine (Ado) and adenosine monophosphate (AMP).
Ado and AMP mediate multiple inflammatory cell responses and have been demonstrated to
be potential biomarkers of neutrophilic airway inflammation in older children and adults
with CF13-15. Moreover, we examined relationships between lung function indices and
purine levels in EBC. Based on known relationships between purines and airway bronchitis
in older children and adults, we hypothesized that EBC purines, particularly AMP, would
correlate with measures of lung function.
Methods
Subjects
Subjects were preschool children (<3 years old) scheduled for clinically indicated iPFTs. All
subjects were at clinical baseline at the time of testing with the exception of one subject who
had collections performed before and after treatment of a CF pulmonary exacerbation.
Subjects were categorized as CF if they met CF Foundation guidelines for the diagnosis16.
Subjects were excluded if they woke before EBC collection could be attempted. This study
was IRB approved and informed consent was obtained from subject parents prior to sample
collection.
Infant Lung Function Testing
Infant pulmonary function tests were performed according to the guidelines of the American
Thoracic Society and European Respiratory Society using the nSpire Infant Pulmonary
Laboratory (nSpire Health, Inc., Longmont, CO)17,18. Patients were sedated with oral
chloral hydrate based on the UNC Hospitals Sedation Guidelines; each subject’s heart rate,
oxygen saturation and respiratory rate were monitored and documented throughout the
procedure. Z-scores were calculated using previously reported reference equations19, 20.
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Collection of EBC from infants and preschoolers was performed by connecting the RTube
EBC collection device (Respiratory Research, Inc., Charlottesville, VA) to the exhalation
port of the nSpire Infant Pulmonary Laboratory, with the RTube chilled using a chiller
sleeve held at −20°C prior to collection (Figure 1). EBC was collected during 10 minutes of
tidal breathing either at the end of the procedure or during the 15 minute waiting period after
administration of albuterol in those subjects receiving post-bronchodilator testing (13 of 15
subjects). Pulse oximetry and respiratory rates were recorded throughout the collection. EBC
samples were extracted from the RTube and stored at −80°C until analyzed.
Mass spectrometric analysis
Mass spectrometry was used to measure EBC concentrations of adenosine, AMP, and urea
as previously described13,14. Briefly, an internal standard solution containing stable isotope
was added to an aliquot of EBC at a ratio of 1:20 of the EBC volume, then the EBC plus
internal standard solution was lyophilized to dryness and re-suspended in 25 μl of HPLC-
grade water yielding an average of 14.4±5.2 fold increase in concentration. Ten μl of the
lyophilized solution was injected onto a C18 column (Acquity UPLC HSS T3 1.8 μm),
separated using 0.1% formic acid and methanol gradients, then analyzed on a triple
quadrupole mass spectrometer (TSQ Quantum Ultra Mass Spectrometer, ThermoFinnigan,
San Jose, CA) using selected reaction monitoring. All samples were assessed in duplicate
and the mean was used for analysis. Of the 15 samples analyzed, two were eliminated from
further analysis: one with low internal standard concentrations suggesting technical error
and another as an outlier with biomarker concentrations >4 standard deviations from the
mean, suggesting contamination. In a third EBC sample in which AMP was below detection
limits, the AMP concentration was assigned as ½ the lowest measured concentration in other
samples.
Statistical analyses
were performed using parametric statistical methods (Pearson for correlations, Student’s T-
test for between group differences) using GraphPad Prism 5.0. EBC values were log
transformed prior to analysis, based on data distributions observed in previous, larger
studies13. All data is presented as means ± standard deviations.
Results
Collection and measurement of EBC biomarkers
EBC collection was attempted during 17 iPFT studies on 16 subjects, including 11 with CF
and 5 with other chronic respiratory diseases (3 primary ciliary dyskinesia (PCD)21, 1
recurrent cough, 1 surfactant protein deficiency post lung transplant). Demographic data are
summarized in Table 1. All subjects were at clinical baseline at the time of study, with the
exception of one subject who had EBC collection with iPFTs before and after treatment of a
CF pulmonary exacerbation. Pathogens were identified on most recent respiratory culture in
47% of subjects. The most common pathogens were Pseudomonas (n=4), Staphylococcus
(n=2) and Haemophilus (n=2) species and were recovered in both CF and non-CF groups.
EBC was successfully collected in 15 out of 17 attempts, including the one subject who had
collections before and after antibiotic treatment for a CF pulmonary exacerbation.
Successful EBC collection was defined as a condensate volume greater than or equal to 100
μL based on our experience with EBC analysis. All but two of the successful collections
were obtained after albuterol administration. There were no obvious differences notable
between the biomarker concentrations in these samples. EBC collection was not associated
with any significant changes in oxygen saturation or respiratory rate (Table 2).
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Airway purines are detected in small volumes of EBC and correlate with infant lung
function
Biomarkers were successfully measured via mass spectrometry in 13 of the 15 EBC
samples. Based on analysis of standard curves for these experiments, we would estimate
limits of detection at 5μM for urea and 1nM for AMP and Ado. Our biomarker
concentrations were generally near these limits of detection, ranging from 3.4 to 124 μM for
urea (27.2±33.42), 1.0 to 7.8 nM for adenosine (4.15±4.35), and 1.0 to 13.5 nM for AMP
(5.87±7.97).
Relationships between EBC biomarkers and iPFT measures
To assess the relationship between EBC biomarkers and iPFT measures, controlling for the
known variable incorporation of airway secretions within EBC was needed14. Although we
previously utilized ratios of biomarkers to the dilution marker urea to control for this
variability13, 14, 22, the measured EBC urea concentrations in this study were often below
reliable quantification limits suggesting poor dependability as a dilution marker. Indeed, the
adenosine to urea (Ado/Urea) and AMP/Urea ratios were not correlated with any iPFT
measures (not shown).
Alternatively, ratios of biomarkers to each other can also be used to control for dilution. We
examined ratios of AMP/Ado since this ratio has been previously shown to correlate with
neutrophilic inflammation in bronchoalveolar lavage fluid. 15 In spirometric flow measures,
the EBC AMP/Ado ratio negatively correlated with forced vital capacity (FVC) in the subset
with CF (r=−0.72 p=0.043), although not in the group as a whole (Figure 2A). EBC AMP/
Ado negatively correlated with forced expiratory volume in 0.5 seconds (FEV0.5) in both the
group as a whole (r=−0.71, p<0.01) and the subset with CF (r=−0.90, p<0.01) (Figure 2B).
EBC AMP/Ado was not significantly correlated with forced expiratory flows between 25
and 75% of volume (FEF25-75) or flows at 75% volume (FEF75) in the entire group or the
subset with CF. Of note, the ratio of AMP/Ado was log transformed based on our previous
experience with larger EBC biomarker data sets. All findings remain significant even
without log transformation prior to analysis.
In plethysmographic volume measures, EBC AMP/Ado was positively correlated with
residual volume (RV) (r=0.64, p<0.020, Figure 2C) and the ratio of residual volume to total
lung capacity (RV/TLC) (r =0.66, p=0.015, Figure 2D) in the group as a whole. The latter
relationship remained statistically significant in the subset with CF (r=0.74, p=0.037), with
the correlation between EBC AMP/Ado. We did not observe any correlations between EBC
AMP/Ado and functional residual capacity (FRC) or total lung capacity (TLC) in the whole
group or the subset with CF.
We did not observe a significant difference between EBC AMP/Ado in the CF and non-CF
groups (p=0.769). Interestingly, in the one subject in whom we had paired values, the EBC
AMP/Ado ratio was lower in the sample obtained after intravenous antibiotic treatment
relative to the sample obtained before treatment.
Discussion
EBC can be safely collected from sedated infants undergoing iPFTs using commercially
available equipment. Consistent with previous studies23-25, EBC collection was well
tolerated without any measurable changes in respiratory rate or oxygen saturation. The EBC
AMP/Ado ratio correlated with infant lung function indices of airway obstruction.
Additionally, EBC volumes were sufficient to measure our purine biomarkers.
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More significantly, we observed that the EBC AMP/Ado ratio correlates with infant lung
function indices of airway obstruction. The simplest interpretation is that the EBC AMP/
Ado is a biomarker of neutrophilic inflammation, which has been shown to correlate with
iPFT measures in children with CF experiencing an exacerbation26. In particular, the
observed relationship between EBC AMP/Ado and plethysmographic findings are similar to
those reported by Peterson-Carmichael et al., who found that RV/TLC correlated directly
with % neutrophils in BALF. However, the relationships between inflammatory markers and
spirometric measures were somewhat different in the two studies, these differences could
reflect the relatively small sample size in both studies. Additionally, mid-expiratory flows
are among the most sensitive, but also most variable measures of small airways obstruction.
The coefficient of variation in our study was higher for FEF25-75 than for any other lung
function measure. This variability can make it difficult to observe relationships when the
sample size is small, and we suspect that was the case here. Ultimately, their conclusion was
similar to ours in that markers of neutrophilic inflammation are correlated with increased
airways obstruction. Furthermore, we have previously demonstrated that the AMP/Ado ratio
in bronchoalveolar lavage fluid from older children correlated with percent neutrophils as
well as with FEV115; our findings in preschoolers may represent the same pathophysiology.
Although our previous studies have shown that AMP is elevated in EBC from older children
in CF, we have not observed elevated AMP/Ado ratio in CF relative to healthy controls. It is
possible that this discrepancy reflects differences between acute and chronic airway
inflammation. Our previous study involved an older CF population (average age 12.6±3.7
years)13 with more established, chronic airway inflammation. Such chronic inflammation
has been associated with elevated EBC adenosine in many diseases22, 27, and we observed a
trend towards elevated EBC Ado/Urea in the CF population in our previous study13. Many
of these older children with CF also exhibited symptoms of asthma, which is a common co-
morbidity associated with increased airway adenosine. Increased airway adenosine from
chronic airway inflammation and/or asthma may have reduced the AMP/Ado ratio even in
the context of elevated AMP from neutrophilic inflammation.
Limitations to this study include a relatively small number subjects, which while sufficient
to demonstrate feasibility may have been too small to detect subtle relationships.
Additionally, the timing of collection was chosen to minimize interference with the iPFTs,
either after testing was complete or during the gap between pre and post-albuterol testing.
Therefore, we cannot exclude the possibility that the iPFT procedure and/or albuterol
administration affected our EBC purine measurements. At present, EBC collection is
primarily an additional tool for those centers with the specialized equipment and personnel
to perform iPFTs, however, the value lies in the fact that it adds a potential measure of lower
airways inflammation that can otherwise only be obtained via bronchoscopy in this young
population.
The positive findings from this study may be sufficient to justify modifying the iPFT
protocol in future studies to allow EBC collection prior to testing; thereby, eliminating these
potential confounders. Follow-up studies examining EBC biomarkers before and after
antibiotic treatment and before and after albuterol would be necessary to validate
preliminary evidence in this study. Furthermore, future studies exploring collection from
non-sedated infants and preschoolers could certainly broaden the applicability of the EBC
approach. Additionally, EBC AMP/Ado measurements could serve as an outcome measure
in clinical trials that include iPFTs, especially for therapies predicted to improve airway
inflammation. Additionally, biomarkers may add information about other aspects of lower
airways disease; e.g., specific infections. Moreover, new techniques in sample collection
(RTube connected to facemask) and analysis (more sensitive MS) may allow transition of
this technology to the outpatient setting.
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In summary, our results show that EBC can be safely collected from young children
undergoing iPFTS and that EBC purine biomarkers may have utility in assessing lower
airway inflammation in this vulnerable population. While promising, additional
investigations are needed to validate the utility of EBC purines and other biomarkers in
infants and preschoolers.
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All CF non-CF
n =* 17 12 5
Age (years)** 2.3±0.8 2.1±0.9 2.6±0.4
Gender, male (%) 6 (35%) 4 (33%) 2 (40%)
Pathogens on culture*** 8 (47%) 5 (42%) 3 (60%)
**
Data expressed as mean in years ± standard deviation
***
Most common pathogens were Pseudomonas (n=4), Staphylococcus (n=2) and Haemophilus (n=2) species and were recovered in both CF and
non-CF groups.
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Table 2
EBC collection
Number of attempts (n) 17
Number of successful collections 15
EBC volume, successful collections 360±130 μl
Oxygen saturations
  Start collection 96.9±1.6
  End collection 96.8±1.7
  P-value 0.389
Respiratory rates
  Start collection 35.2±7.5
  End collection 34.6±7.9
  P-value 0.443
*
Data expressed as means ± standard deviation
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